Neutropenia  >>  oxaliplatin 
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
PRESERVE 1, NCT04607668 / 2019-003826-25: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Jan 2023 - Jun 2023: From PRESERVE1 trial for metastatic colorectal cancer
Checkmark Approved Clinical Trial Application in China for metastatic CRC
Apr 2021 - Apr 2021: Approved Clinical Trial Application in China for metastatic CRC
Terminated
3
326
Europe, US, RoW
Trilaciclib, G1T28, CDK 4/6 inhibitor, Placebo
G1 Therapeutics, Inc.
Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
02/23
03/23
LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/)

Hourglass Jan 2022 - Jan 2022 : Data from LEAP trial in combination with Keytruda for esophageal squamous cell carcinoma at ASCO-GI 2022
Recruiting
3
862
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL®
Merck Sharp & Dohme LLC, Eisai Inc.
Metastatic Esophageal Squamous Cell Carcinoma
12/25
12/25
LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/)

Active, not recruiting
3
890
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU
Merck Sharp & Dohme LLC, Eisai Inc.
Advanced/Metastatic Gastroesophageal Adenocarcinoma
02/26
02/26
ULTIMA, NCT04611724: A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer

Recruiting
2
35
RoW
FOLFIRINOX
Asan Medical Center, Green Cross Corporation, Boryung Pharmaceutical Co., Ltd
Urachal Cancer
12/23
09/24
2012-003678-13: Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma

Not yet recruiting
1/2
118
Europe
Powder for suspension for injection, Powder for solution for infusion, Solution for infusion, Solution for injection, ABRAXANE, GEMCITABINE, OXALIPATINE, CAMPTO, FOLINATE DE CALCIUM, FLUOROURACILE
Institut Régional de Cancerologie de Montpellier - Val d’Aurelle, Laboratory CELGENE
metastatic pancreatic adenocarcinoma, Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed
1/2
126
US
PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893
SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics
Metastatic Pancreatic Adenocarcinoma
04/19
11/23
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02671435 / 2016-000662-38: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Hourglass Jan 2021 - Dec 2022 : From trial in combination with monalizumab for solid tumors
Hourglass Jan 2021 - Dec 2021 : Data from P2 expansion cohort 3 of P1/2 trial in combination with monalizumab and cetuximab for SCCHN
Checkmark Combination trial with monalizumab at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Combination trial with monalizumab at ASCO 2018 [screenshot]
Checkmark Combination study with NKG2A
More
Active, not recruiting
1/2
383
Europe, Canada, US, RoW
Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
MedImmune LLC
Advanced Solid Tumors
10/21
09/24
NCT02135887: A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.

Recruiting
N/A
184
RoW
MB-6, Folinic acid; Fluorouracil ; Oxaliplatin, Placebo
Microbio Co Ltd
Stage III Colorectal Cancer, Neutropenia
03/22
12/22

Download Options